Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Adding chemotherapy or anti-VEGF to immunotherapy is an emerging strategy to enhance the
efficacy of immunotherapy in many cancers. This phase 2 study aims to explore the preliminary
efficacy of combination pembrolizumab with lenvatinib and chemotherapy in NSCLC patients with
sensitizing EGFR, ALK, or ROS1 genetic aberration refractory to standard targeted therapy.